The announcement comes on the heels of Curio’s recent 510(k) clearance from the US Food and Drug Administration (FDA) for its prescription digital therapeutic device, MamaLift Plus, as a symptomatic treatment for postpartum depression (PPD).
CURIO RAISES INVESTMENT FOR WOMEN’S MENTAL HEALTH
Previous
Previous
ONCE VENTURES AT THE 2025 NUTRA HEALTHSPAN SUMMIT
Next
Next